Group 1 - The core point of the article is that Boyuan Co., Ltd. held its 11th meeting of the second board of directors on October 23, 2025, to discuss the adjustment of the audit committee members [1] - For the year 2024, Boyuan Co., Ltd. reported that its revenue composition is entirely from the chemical industry, with a 100.0% share [1] - As of the time of reporting, Boyuan Co., Ltd. has a market capitalization of 12 billion yuan [1] Group 2 - The article highlights that the Chinese innovative drug sector has generated 80 billion USD in overseas licensing deals this year [1] - It features an interview with Lu Gang, a partner at Chuangdong Investment, discussing the hot secondary market in biomedicine while noting the cooling of fundraising in the primary market [1]
博苑股份：10月23日召开董事会会议